Sun Pharmaceutical Industrie (Sun Pharma) and LIB Therapeutics Inc (LIB) have entered an exclusive licensing agreement, under which Sun Pharma has been granted rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China. Lyrokaul (lerodalcibep), a once-monthly PCSK9 inhibitor for LDL-C lowering, comes with 6-month EU ambient storage; received EU approval on September 21, 2026. The agreement strengthens Sun Pharma’s Innovative Medicines portfolio.
Under the agreement, LIB will receive an upfront and future milestone payments, together with royalties based on net sales in the licensed territories. Sun Pharma will be responsible for pursuing regulatory approvals in licensed territories where approval has not yet been obtained.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
